Monica Bartolomei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Monica Bartolomei has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Paola Bertocchi
Dipartimento del Farmaco, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
11 shared publications - Eleonora Antoniella
Dipartimento del Farmaco, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
10 shared publications - Maria Cristina Gaudiano
Chemical Medicines Unit, National Centre for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, Rome, Italy
9 shared publications - Livia Manna
Dipartimento del Farmaco, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
8 shared publications - Luisa Valvo
Dipartimento del Farmaco, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
8 shared publications - Andrea Luca Rodomonte
Dipartimento del Farmaco, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
6 shared publications
Latest Publications
- Open Access
- 27 March 2024
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 12 (2) , qfae018
Illegal products containing selective androgen receptor modulators purchased online from Italy: health risks for consumers
Background: Selective androgen receptor modulators (SARMs) are small synthetic drug molecules that are still not approved as medicine in Europe or the United States but are sold on illegal websites to improve sport performance, particularly bodybuilding. Aim: To address the quality issues of illegal SARM products and their increasing diffusion in Italy with their potential health risks for consumers. Methods: Web-based tools were used to investigate retail websites, trending searches, and information exchange via social media. Thirteen SARM products, purchased on retail websites accessible from Italy, were subject to visual inspection and chemical analysis by mass spectrometry and quantitative nuclear magnetic resonance. Outcomes: The primary outcome was demonstration of additional health risks due to the illicit presence of other active ingredients, contamination, and misdosage in SARM products sold on the internet. The secondary outcome was to show the increasing trend of interest in Italy for these products. Results: Most websites reported misleading information; specifically, the statement “for research only” was reported notwithstanding indications on dosage and training phases. The trending search showed that interest toward SARMs increased in Italy in the last years. The use of these products is clearly encouraged by the emerging phenomenon of “broscience” as revealed in socials. Visual inspection evidenced nonconform labeling. Qualitative analysis confirmed the presence of the stated SARM in about 70% of samples. In 23% of samples, the expected SARM was not detected but a different one instead, and in 1 sample, no SARMs were detected. Other undeclared pharmaceutical substances (tamoxifen, clomifene, testosterone, epimethandienone, tadalafil) were measured in 30% of samples. The copresence of >1 active substance was observed in >60% of samples. Quantitative nuclear magnetic resonance data showed nonuniform content ranging from 30% to 90% of the label claim. Clinical Implications: The use of SARMs, in the presence of unexpected life-threatening reactions in persons using the products to increase sport performance, should be assessed. Strengths and Limitations: This investigation involved an integrated approach to study SARM products and related sociologic aspects. The main shortcomings are the limited number of samples and retail websites in the clear web investigated. Conclusion: SARMs sold online as food supplement–like products represent a health hazard due to the presence of unapproved and undeclared active substances. The presence of contaminants clearly indicates the absence of good manufacturing practices in the production, which increases the health risks.
- 27 March 2024
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 12 (2) , qfae018
Open AccessIllegal products containing selective androgen receptor modulators purchased online from Italy: health risks for consumers
Background: Selective androgen receptor modulators (SARMs) are small synthetic drug molecules that are still not approved as medicine in Europe or the United States but are sold on illegal websites to improve sport performance, particularly bodybuilding. Aim: To address the quality issues of illegal SARM products and their increasing diffusion in Italy with their potential health risks for consumers. Methods: Web-based tools were used to investigate retail websites, trending searches, and information exchange via social media. Thirteen SARM products, purchased on retail websites accessible from Italy, were subject to visual inspection and chemical analysis by mass spectrometry and quantitative nuclear magnetic resonance. Outcomes: The primary outcome was demonstration of additional health risks due to the illicit presence of other active ingredients, contamination, and misdosage in SARM products sold on the internet. The secondary outcome was to show the increasing trend of interest in Italy for these products. Results: Most websites reported misleading information; specifically, the statement “for research only” was reported notwithstanding indications on dosage and training phases. The trending search showed that interest toward SARMs increased in Italy in the last years. The use of these products is clearly encouraged by the emerging phenomenon of “broscience” as revealed in socials. Visual inspection evidenced nonconform labeling. Qualitative analysis confirmed the presence of the stated SARM in about 70% of samples. In 23% of samples, the expected SARM was not detected but a different one instead, and in 1 sample, no SARMs were detected. Other undeclared pharmaceutical substances (tamoxifen, clomifene, testosterone, epimethandienone, tadalafil) were measured in 30% of samples. The copresence of >1 active substance was observed in >60% of samples. Quantitative nuclear magnetic resonance data showed nonuniform content ranging from 30% to 90% of the label claim. Clinical Implications: The use of SARMs, in the presence of unexpected life-threatening reactions in persons using the products to increase sport performance, should be assessed. Strengths and Limitations: This investigation involved an integrated approach to study SARM products and related sociologic aspects. The main shortcomings are the limited number of samples and retail websites in the clear web investigated. Conclusion: SARMs sold online as food supplement–like products represent a health hazard due to the presence of unapproved and undeclared active substances. The presence of contaminants clearly indicates the absence of good manufacturing practices in the production, which increases the health risks.
- 1 August 2012
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 9 (8) , 2130-2137
A Survey on Illegal and Counterfeit Medicines for the Treatment of Erectile Dysfunctions in Italy
In developed countries the phenomenon of pharmaceutical counterfeiting is steadily increasing through the illegal and the Internet market. Medicines for the treatment of erectile dysfunctions containing phosphodiesterase type 5 inhibitors (PDE5) are especially prone to falsification. To obtain evidence of the health risks for patients taking these products and to provide useful information to general practitioners and specialists in sexual medicine. First the samples were visually inspected and then analyzed to get information about their identity and quality. A survey on the PDE5 medicines analyzed by the Italian official medicines control laboratory between 2005 and 2011 was performed. All the analyzed medicines were gathered from the Italian illegal market (seizures by police forces) or were bought from illegal online pharmacies. Results. The study revealed that 24% of the analyzed samples were counterfeit and 54% were illegal medicines. In 12% of the cases an intermediate classification (illegal/counterfeit) was assigned. Only 7% of the samples were original. Moreover, the examination of the packaging evidenced potential risks: outer and immediate packaging missing; inconsistency between the carton box and the blister as regards the expiry date and/or the batch number; expiry date or manufacturer's name or country missing. In 19% of the samples a potential health risk for patients was identified due to either the presence in the sample of more than one undeclared PDE5(s) or an amount of the active ingredient higher than that declared (up to 190% of the maximum dose) or to the presence of potentially dangerous excipients of non-pharmaceutical origin or quality (e.g., gypsum or non-purified talc).
- 1 August 2012
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 9 (8) , 2130-2137
A Survey on Illegal and Counterfeit Medicines for the Treatment of Erectile Dysfunctions in Italy
In developed countries the phenomenon of pharmaceutical counterfeiting is steadily increasing through the illegal and the Internet market. Medicines for the treatment of erectile dysfunctions containing phosphodiesterase type 5 inhibitors (PDE5) are especially prone to falsification. To obtain evidence of the health risks for patients taking these products and to provide useful information to general practitioners and specialists in sexual medicine. First the samples were visually inspected and then analyzed to get information about their identity and quality. A survey on the PDE5 medicines analyzed by the Italian official medicines control laboratory between 2005 and 2011 was performed. All the analyzed medicines were gathered from the Italian illegal market (seizures by police forces) or were bought from illegal online pharmacies. Results. The study revealed that 24% of the analyzed samples were counterfeit and 54% were illegal medicines. In 12% of the cases an intermediate classification (illegal/counterfeit) was assigned. Only 7% of the samples were original. Moreover, the examination of the packaging evidenced potential risks: outer and immediate packaging missing; inconsistency between the carton box and the blister as regards the expiry date and/or the batch number; expiry date or manufacturer's name or country missing. In 19% of the samples a potential health risk for patients was identified due to either the presence in the sample of more than one undeclared PDE5(s) or an amount of the active ingredient higher than that declared (up to 190% of the maximum dose) or to the presence of potentially dangerous excipients of non-pharmaceutical origin or quality (e.g., gypsum or non-purified talc).
- 27 April 2010
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 53 (2) , 215-220
Counterfeit drugs detection by measurement of tablets and secondary packaging colour
- 27 April 2010
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 53 (2) , 215-220
Counterfeit drugs detection by measurement of tablets and secondary packaging colour
- 1 September 2008
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 48 (2) , 477-481
Different crystal morphologies arising from different preparation methods of a same polymorphic form may result in different properties of the final materials: The case of diclofenac sodium trihydrate
- 1 September 2008
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 48 (2) , 477-481
Different crystal morphologies arising from different preparation methods of a same polymorphic form may result in different properties of the final materials: The case of diclofenac sodium trihydrate
- 1 September 2008
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 48 (2) , 303-309
An LC method for the simultaneous screening of some common counterfeit and sub-standard antibiotics
- 1 September 2008
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 48 (2) , 303-309
An LC method for the simultaneous screening of some common counterfeit and sub-standard antibiotics
- 1 November 2007
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 45 (3) , 443-449
Hydrate modifications of the non-steroidal anti-inflammatory drug diclofenac sodium: Solid-state characterisation of a trihydrate form
- 1 November 2007
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 45 (3) , 443-449
Hydrate modifications of the non-steroidal anti-inflammatory drug diclofenac sodium: Solid-state characterisation of a trihydrate form
- 11 September 2006
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 42 (1) , 56-63
Uncertainty evaluation in the chloroquine phosphate potentiometric titration: Application of three different approaches
- 11 September 2006
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 42 (1) , 56-63
Uncertainty evaluation in the chloroquine phosphate potentiometric titration: Application of three different approaches